Skip to main content
2024 Guide to Patient Support Services

Lilly Oncology

2024 PSS Guide

Lilly Oncology Support Center

Eli Lilly and Company, through Lilly Oncology, offers financial assistance to qualified patients who are prescribed oncology medications and who need help paying for their medications. The complete list of Lilly Oncology drugs and their patient support programs is provided in the Table.

Lilly Oncology Support Center

The Lilly Oncology Support Center provides services to patients and providers, including assistance with infused products, the Retevmo Support Program, the Verzenio Continuous Care support program, and the Lilly Cares Foundation.

Infused Products Enrollment Form

By enrolling in the Lilly Oncology Support Center, patients may receive various forms of support and information to help access infused oncology products, including benefits investigation support, financial support, and ongoing support. To enroll your patient, complete the application at LillyOncologySupport.com and fax to 877-366-0585.

Jaypirca Continuous Care Program

This program provides ongoing support services for patients who have been prescribed Jaypirca, including the Jaypirca Savings Card, the Jaypirca Interim Access Program, the MyRightDose Program, and other support services. To be eligible for the Jaypirca Continuous Care Program, patients must be aged ≥18 years, have been prescribed Jaypirca for an FDA-approved indication, and meet the eligibility requirements. To enroll your patient, complete the application at Jaypirca.com and fax to 855-511-2515. The Jaypirca Savings Card allows eligible commercially insured patients to pay as little as $0 for a 30-day supply of Jaypirca. For more information on the Jaypirca Savings Card program, call 833-727-4589. This program is subject to monthly and annual caps. The Jaypirca MyRightDose Program allows patients who are prescribed Jaypirca to continue therapy with Jaypirca at the appropriate dose, without delays or costs to the patient. Jaypirca can be shipped to the patients as early as 48 hours after enrollment in the MyRightDose Program.

Retevmo Support Program

This program provides ongoing support services for patients who have been prescribed Retevmo, including the Retevmo Savings Card, the MyRightDose Program, the Retevmo Interim Access Program support, and other support services. To enroll your patient, complete the application, Retevmo Support Program online.

The Retevmo Savings Card allows eligible commercially insured patients to pay as little as $0 for a 30-day supply of Retevmo for up to 12 months with an annual cap of $25,000.

The Retevmo MyRightDose Program allows patients who are prescribed Retevmo to continue therapy with Retevmo at the appropriate dose, without delays or costs to the patient. Retevmo can be shipped to the patients as early as 48 hours after enrollment in the MyRightDose Program.

The application for the Retevmo MyRightDose Program is available at Retevmo.com. The completed form should be faxed to 844-372-9043. For more information on the MyRightDose Program for Retevmo, call 833-290-2175 or visit Retevmo.com.

Verzenio Continuous Care Program

This program provides ongoing support services for patients who have been prescribed Verzenio, including the Verzenio Savings Card, the MyRightDose Program, the Companion in Care Program, and other support services. To be eligible for the Verzenio Continuous Care Program, patients must be aged ≥18 years, have been prescribed Verzenio for an FDA-approved indication, and meet the eligibility requirements. To enroll your patient, complete the application at and fax to 855-545-5957.

The Verzenio Savings Card allows eligible commercially insured patients to pay as little as $0 for a 28-day supply of Verzenio. This program is subject to monthly and annual caps. For more information on the Verzenio Savings Card program, call 844-837-9364.

The Verzenio MyRightDose Program allows patients who are prescribed Verzenio to continue therapy with Verzenio at the appropriate dose, without delays or costs to the patient. Verzenio can be shipped to the patients as early as 48 hours after enrollment in the MyRightDose Program.

The application for the Verzenio MyRightDose Program is available at Verzenio.com/Enrollment_Form. The completed form should be faxed to 833-665-6329. For more information on the MyRightDose Program for Verzenio, call 833-557-2417 or visit Verzenio.com.

Once enrolled in the Verzenio Continuous Care Program, patients have access to the Companion in Care Program. This program provides patients with help from the same person every time to clarify treatment expectations, provide emotional support, answer questions about side effects, and guide patients back to your practice for medical advice.

Lilly Cares Foundation

The Lilly Cares Foundation provides the Patient Assistance Program for uninsured or underinsured patients who have been prescribed Lilly Oncology medications.

For more information, including eligibility criteria, please visit LillyCares.com.

TABLE Lilly Breast Cancer Treatment

Drug
Indications
Patient support programs

Drug
Alimta (pemetrexed) for injection
Indications
Patient support programs




Drug
Portrazza (necitumumab) injection
Indications
First-line treatment of metastatic squamous non–small cell lung cancer, in combination with gemcitabine and cisplatin
Patient support programs


Drug
Verzenio (abemaciclib) tablets
Indications
Patient support programs

HR indicates hormone receptor; NSCLC, non–small-cell lung cancer.

Alimta (pemetrexed) for injection Indications

Initial treatment in combination with pembrolizumab and platinum chemotherapy for nonsquamous metastatic non–small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations; initial treatment in combination with cisplatin for locally advanced or metastatic nonsquamous NSCLC; single agent in recurrent metastatic nonsquamous NSCLC after prior chemotherapy; single agent as maintenance therapy in patients with locally advanced or metastatic nonsquamous NSCLC whose disease has not progressed after 4 cycles of platinum-based first-line chemotherapy; in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery

Cyramza (ramucirumab) Indications

As a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy; in combination with erlotinib, for first-line treatment of metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) mutations; in combination with docetaxel, for treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Cyramza. In combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine; as a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib

Erbitux (cetuximab) Indications

Treatment of locally or regionally advanced squamous-cell carcinoma of the head and neck (SCCHN), in combination with radiation; treatment of patients with recurrent locoregional disease or metastatic SCCHN, in combination with platinum-based therapy; treatment of recurrent or metastatic SCCHN after progressing on platinum-based therapy; treatment of metastatic colorectal cancer that is EGFR-expressing, KRAS wild-type, as determined by an FDA-approved test: as first-line treatment, in combination with FOLFIRI or in combination with irinotecan, in disease refractory to irinotecan-based chemotherapy; as a single agent in patients progressing after oxaliplatin- and irinotecan-based chemotherapy or intolerant to irinotecan

Jaypirca (pirtobrutinib) tablets

Treatment of adult patients with relapsed or refractory mantle cell lymphoma after ≥2 lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received ≥2 prior lines of therapy, including a BTK inhibitor and a B-cell leukemia/lymphoma-2 inhibitor

Retevmo (selpercatinib) capsules Indications

Treatment of adults with locally advanced or metastatic RET fusion–positive non–small cell lung cancer, as detected by an FDA-approved test; treatment of patients aged ≥12 years with advanced or metastatic medullary thyroid cancer and RET mutation, as detected by an FDA-approved test, who require systemic therapy; treatment of patients aged ≥12 years with advanced or metastatic RET fusion–positive thyroid cancer, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine–refractory (if radioactive iodine is appropriate); treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion who have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options

Verzenio (abemaciclib) tablets Indications

In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence; as initial endocrine-based therapy, in combination with an aromatase inhibitor, for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with fulvestrant, for disease that progressed after endocrine therapy; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, as monotherapy, for disease that progressed after endocrine therapy and previous chemotherapy in the metastatic setting